How a 2005 paper by Katalin Karikó and Drew Weissman — a quiet finding about modified nucleosides in RNA — became the intellectual spine of the Moderna, Pfizer–BioNTech, and CureVac vaccines. A story only visible when you overlay scientific citations with patent filings.
In August 2005, the journal Immunity published a paper that nobody outside a small corner of RNA biology particularly wanted to read. Its title was forbidding: "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA." The finding was subtle: if you substitute the uridine in synthetic mRNA with pseudouridine, the immune system stops treating it as foreign. You can inject it. It can make protein. It will not trigger an inflammatory storm.
For fifteen years, that finding sat in the scientific literature, accruing citations at the quiet pace of a successful but specialised paper. Katalin Karikó was demoted at Penn. Then, in January 2020, a novel coronavirus was sequenced, and two small companies — Moderna and BioNTech — reached for the only chemistry that would let them turn a genetic sequence into a vaccine in weeks instead of years. Both had already licensed the Karikó–Weissman patents. Both used 1-methyl-pseudouridine. The 2005 paper, once ignored, became the most consequential piece of chemistry of the twenty-first century.
This dashboard shows what that cascade looks like, scientifically and commercially, in the same view. Every circle on the left is a paper; every square on the right is a patent. The story emerges only when you see both at once.
Then, in 2020, the world discovers the paper all at once. Annual citations to Karikó et al. 2005, by year.
How to read this. Each bar is one year's citations to the 2005 paper. The dormant period before 2020 is not an artifact — it reflects a genuinely small specialist literature. The 2020–2022 spike is what happens when a basic-science result becomes the enabling chemistry of a global public-health response. Distribution estimated from Scite's 2,437 total citing publications.
The journey from foundational science to intellectual property to clinical evidence to Nobel Prize — rendered as a single timeline with two columns.
Ten patents, four assignees, one chemistry. Every mRNA COVID-19 vaccine shipped under the permission structure below — and every one cites the Karikó–Weissman line of work.
Smart Citations — the exact sentences in which later papers and patents credit the 2005 breakthrough. This is citation not as a number but as narrative.